Annexin A1 promotes the progression of bladder cancer via regulating EGFR signaling pathway

Piao Li; Lingling Li; Zhou Li; Shennan Wang; Ruichao Li; Weiheng Zhao; Yanqi Feng; Shanshan Huang; Lu Li; Hong Qiu; Shu Xia

doi:10.1186/s12935-021-02427-4

Annexin A1 promotes the progression of bladder cancer via regulating EGFR signaling pathway

Cancer Cell Int. 2022 Jan 6;22(1):7. doi: 10.1186/s12935-021-02427-4.

Authors

Piao Li^#¹, Lingling Li^#¹, Zhou Li¹, Shennan Wang¹, Ruichao Li², Weiheng Zhao¹, Yanqi Feng¹, Shanshan Huang¹, Lu Li¹, Hong Qiu¹, Shu Xia³

Affiliations

¹ Department of Oncology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, 1095 Jie Fang Avenue, Wuhan, Hubei, 430030, People's Republic of China.
² Department of Geriatric, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan, Hubei, 430030, People's Republic of China.
³ Department of Oncology, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, 1095 Jie Fang Avenue, Wuhan, Hubei, 430030, People's Republic of China. xiashutj@hust.edu.cn.

^# Contributed equally.

Abstract

Background: Bladder cancer (BLCA) is one of the most common malignancies worldwide. One of the main reasons for the unsatisfactory management of BLCA is the complex molecular biological mechanism. Annexin A1 (ANXA1), a Ca²⁺-regulated phospholipid-binding protein, has been demonstrated to be implicated in the progression and prognosis of many cancers. However, the expression pattern, biological function and mechanism of ANXA1 in BLCA remain unclear.

Methods: The clinical relevance of ANXA1 in BLCA was investigated by bioinformatics analysis based on TCGA and GEO datasets. Immunohistochemical (IHC) analysis was performed to detect the expression of ANXA1 in BLCA tissues, and the relationships between ANXA1 and clinical parameters were analyzed. In vitro and in vivo experiments were conducted to study the biological functions of ANXA1 in BLCA. Finally, the potential mechanism of ANXA1 in BLCA was explored by bioinformatics analysis and verified by in vitro and in vivo experiments.

Results: Bioinformatics and IHC analyses indicated that a high expression level of ANXA1 was strongly associated with the progression and poor prognosis of patients with BLCA. Functional studies demonstrated that ANXA1 silencing inhibited the proliferation, migration, invasion and epithelial-mesenchymal transition (EMT) of BLCA cells in vitro, and suppressed the growth of xenografted bladder tumors in vivo. Mechanistically, loss of ANXA1 decreased the expression and phosphorylation level of EGFR and the activation of downstream signaling pathways. In addition, knockdown of ANXA1 accelerated ubiquitination and degradation of P-EGFR to downregulate the activation of EGFR signaling.

Conclusions: These findings indicate that ANXA1 is a reliable clinical predictor for the prognosis of BLCA and promotes proliferation and migration by activating EGFR signaling in BLCA. Therefore, ANXA1 may be a promising biomarker for the prognosis of patients with BLCA, thus shedding light on precise and personalized therapy for BLCA in the future.

Keywords: Annexin A1; Bladder cancer; EGFR signaling; Progression.

Abstract

Grants and funding